Article Details

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and ...

Retrieved on: 2021-12-06 15:05:13

Tags for this article:

Click the tags to see associated articles and topics

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and .... View article details on hiswai:

Excerpt

... and adaptive immune systems, today announced the presentation of interim clinical data from the company's ongoing Phase 1/2 study of BDC-1001, ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up